PrimeCell™ VP of R&D to Discuss Adult Pluripotent Stem Cell Advances
News Jun 16, 2006
PrimeCell™ Therapeutics has announced that its Vice President of Research and Development, Francisco Silva, has been invited to participate in a panel discussion hosted by Sen. Rick Santorum (R-PA) to discuss the Alternative Pluripotent Stem Cells Therapies Enhancement Act (S.2754), which would intensify research into alternative methods of deriving pluripotent stem cells.
PrimeCell Therapeutics' platform allows for the reprogramming of adult germ-line stem cells-PrimeCells-the company's pluripotent proprietary cell line capable of transforming into any cell type.
PrimeCell has already been reprogrammed into heart, nerve, bone and cartilage cells and holds promise for expediting the process from research to therapy.
WHO: Francisco J. Silva, Vice President of Research & Development for PrimeCell Therapeutics.
Silva is a principal contributor to the company's intellectual property portfolio and oversees the development of all therapeutic platforms.
He is responsible for PrimeCell Therapeutics' current scientific progress and designs, and also implements the company's premier research developments.
WHAT: PrimeCell Therapeutics LLC, a recently formed subsidiary of PrimeGen Biotech LLC, is devoted exclusively to adult stem cell reprogramming.
The company has introduced its murine model and initial human results for PrimeCell at several global stem cell conferences.
WHEN: 10:00 am Thursday, June 15th, 2006
WHERE: S-120 U.S. Capitol Building
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019